Overview
Rasagiline is a potent, irreversible inhibitor of monoamine oxidase-B (MAO-B), an enzyme responsible for breaking down dopamine in the brain. Developed as an anti-Parkinsonian agent, it is chemically distinct from earlier MAO-B inhibitors like selegiline. Its primary metabolite, aminoindan, contributes to its therapeutic effects without the amphetamine-like byproducts associated with other drugs in this class. Approved by the FDA in 2006, rasagiline is marketed under the brand name Azilect. It is used both as monotherapy in early-stage Parkinson's disease and as an adjunct to levodopa in advanced cases. Its neuroprotective properties are under ongoing research for potential applications in Alzheimer's disease and other neurodegenerative conditions.
Physical and Chemical Properties
Rasagiline is a white to off-white crystalline powder with a molecular weight of 171.24 g/mol. It has a melting point of approximately 140-142°C and demonstrates solubility in organic solvents like ethanol, while being only slightly soluble in water. The compound is stable under recommended storage conditions but may degrade upon prolonged exposure to light or moisture. Its molecular formula (C12H13N) reflects a relatively simple structure compared to other MAO-B inhibitors. The irreversible binding to MAO-B ensures prolonged pharmacological activity, requiring only once-daily dosing. Analytical methods such as HPLC are commonly used to verify its purity, which is critical for pharmaceutical applications.
Main Applications
Rasagiline's primary application is in managing Parkinson's disease, where it alleviates motor symptoms by preserving dopamine levels in the brain. As monotherapy, it delays the need for levodopa in early-stage patients. In combination with levodopa, it reduces 'off-time' episodes and dyskinesias in advanced cases. Beyond Parkinson's, preclinical studies suggest rasagiline may slow neurodegeneration due to its anti-apoptotic and antioxidant effects. Research is exploring its efficacy in Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and depression. However, these uses remain investigational and require further clinical validation.
Safety and Storage
Rasagiline should be stored in a tightly sealed container at 2-8°C, protected from light and moisture to prevent degradation. Handling requires standard laboratory precautions, including gloves and eye protection, to avoid skin contact or inhalation. Pharmacologically, rasagiline has a favorable safety profile but carries risks of hypertensive crisis if combined with tyramine-rich foods or other MAO inhibitors. Concurrent use with SSRIs or SNRIs may trigger serotonin syndrome. Patients should be monitored for interactions, and doses adjusted in hepatic impairment due to its liver metabolism.
B2B Procurement Guide
B2B buyers should prioritize suppliers with Good Manufacturing Practice (GMP) certification to ensure compliance with pharmaceutical standards. Key procurement criteria include verifying the CAS number (161735-79-1) and requesting certificates of analysis (CoA) for purity (typically ≥98%). Bulk purchases may benefit from negotiated pricing, though costs vary by quantity and supplier reputation. Leading manufacturers are located in Europe, India, and China. Due to its niche application, rasagiline is often sourced through specialized chemical distributors or direct from pharmaceutical ingredient producers.